The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological cause of the coronavirus induced disease 19 (COVID-19) that emerged in late 2019 causing a worldwide epidemic. SARS-CoV-2 belongs to the family Coronaviridae together with SARS-CoV that emerged in 2002 causing approximately 8000 infections with a lethality of 10%. Both viruses are the result of a zoonotic transfer from an animal reservoir that caused a life-threatening respiratory illness in humans. Along with other accumulating evidence, our working hypothesis that SARS-CoV-2 convalescent individuals have protective anti-SARS-CoV-2 immunity, and particularly, antibodies. In this study we aim to isolate anti-SARS Co-V-2 broadly neutralizing antibodies (bNAbs) bNAbs from convalescent COVID-19 patients and to generate a panel of candidates for treatment and prevention of COVID-19.